INBX Dividend: Inhibrx Biosciences Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

INBX Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	1	0	1	2	7	12
Revenue Growth (YoY)	0%	-100%	-50%	-71%	-42%	-8%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	30	127	29	20	12	6
Research & Development	92	201	190	109	70	73
Operating Expenses	125	331	221	131	83	80
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-120	1,687	-239	-145	-81	-75
Income Tax Expense	0	0	0	0	0	0
Net Income	-120	1,687	-241	-145	-81	-76
Net Income Growth	-107%	-800%	66%	79%	7%	49%
Shares Outstanding (Diluted)	15.46	14.98	47.13	40.11	38.01	37.71
Shares Change (YoY)	4%	-68%	18%	6%	1%	3%
EPS (Diluted)	-7.78	112.62	-5.12	-3.62	-2.15	-2.02
EPS Growth	-107%	-2,299%	41%	68%	6%	44%
Free Cash Flow	-140	-197	-197	-115	-81	-49
Free Cash Flow Per Share	-9.05	-13.14	-4.17	-2.86	-2.13	-1.29
Gross Margin	--	--	--	--	--	--
Operating Margin	-12,400%	0%	-21,900%	-6,450%	-1,085.71%	-558.33%
Profit Margin	-12,000%	0%	-24,100%	-7,250%	-1,157.14%	-633.33%
Free Cash Flow Margin	-14,000%	0%	-19,700%	-5,750%	-1,157.14%	-408.33%
EBITDA	-122	-329	-218	-128	-75	-66
EBITDA Margin	-12,200%	0%	-21,800%	-6,400%	-1,071.42%	-550%
D&A For EBITDA	2	2	1	1	1	1
EBIT	-124	-331	-219	-129	-76	-67
EBIT Margin	-12,400%	0%	-21,900%	-6,450%	-1,085.71%	-558.33%
Effective Tax Rate	0%	0%	0%	0%	0%	0%